Rheumatoid Arthritis

Results call attention to the potential for early intervention and risk stratification for developing RA based on remnant cholesterol.

Patients with rheumatoid arthritis who received acupuncture had a lower cumulative incidence of ischemic stroke compared to those who did not.

Mark Bleackley, PhD, discusses the upcoming phase 2 trial of IHL-675A designed to explore arthritis treatment through dual-drug comparison, promising global expansion, and its impact on patients’ pain relief.

Multivariable analyses found genetic predispositions to overall rheumatoid arthritis with decreased sleep duration, as well as a significant genetic association between seropositive rheumatoid arthritis and insomnia symptoms.

Results demonstrated IHL-675A was well-tolerated, with no concerning adverse events or serious adverse events reported.

Four themes emerged from the data, including the positive impact of exercise on sleep, positive experiences of the exercise intervention, mental health benefits, and achieving empowerment and ownership during the exercise process.

The 2021 ACR Guideline for the Treatment of Rheumatoid Arthritis provides updated recommendations for the pharmacologic management of RA. In honor of Rheumatoid Arthritis Awareness Day, test your knowledge with this quiz:

The presence of mental health, pain-related illnesses, and metabolic diseases were significantly associated with the worsening of arthritis-related pain, severity, and disease activity.

How well do patients with rheumatoid arthritis adhere to treatment with a TNF inhibitor and how likely and long lasting is remission? Test your knowledge with this quiz.

Improvements in insulin resistance were reported in patients with RA and type 2 diabetes treated with tofacitinib.

As gastrointestinal (GI) symptoms are common in the US, how does rheumatoid arthritis (RA) affect the frequency of GI events? Test your knowledge with this quiz.

Entering menopause prior to age 45 was associated with a 46% increased risk of developing RA compared with those who began menopause at ≥50 years.

Serum-COMP was linked to an increased risk of both cardiovascular disease and coronary artery disease.

Results indicated patients with GERD are at a 69% increased risk of developing RA.

Laura Donlin, PhD, highlights the significance of identifying new subtypes of rheumatoid arthritis, emphasizing the potential for a paradigm shift in RA treatment toward personalized care and early interventions.

Nonsteroidal anti-inflammatory drug use and prednisolone equivalent dose >5 mg per day were associated with an increased risk of NAFLD, whereas hydroxychloroquine use and prednisolone equivalent dose ≤5 mg per day were associated with a decreased risk of NAFLD.

Peter C Taylor, PhD, discusses the efficacy and safety of nipocalimab in patients with active rheumatoid arthritis.

Expert rheumatologists discuss precision medicine in rheumatoid arthritis. In particular, they discuss available data and the value of various tools in guiding treatment selection in routine clinical practice.

Expert rheumatologists discuss precision medicine in rheumatoid arthritis. In particular, they discuss available data and the value of various tools in guiding treatment selection in routine clinical practice.

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.

This data presented at ACR 2023 may provide relief to pregnant mothers as many stop taking them out of fear of harm to the fetus.

This new program was designed to be a scalable model for the formulation of similar initiatives in communities known to have limited access to specialized care for rheumatic conditions.

This new research presented at ACR Convergence 2023 led to several notable findings for patients with rheumatoid arthritis.

The indication for the intravenous formulation is for adults with RA, as well as adults and children with either active PJIA or systemic JIA.